ESMO 2025：基石药业-B揭晓CS2009(PD-1/VEGF/CTLA-4三特异性抗体)Ⅰ期临床试验数据

Core Insights - The company announced the presentation of preliminary data from its Phase I clinical study of CS2009 (a PD1/VEGF/CTLA-4 trispecific antibody) at the 2025 European Society for Medical Oncology (ESMO) annual meeting [1] - The company also revealed the design of its Phase Ib clinical study for CS5001 (a ROR1 antibody-drug conjugate) [1] Summary by Categories - Clinical Research Updates - Preliminary data for CS2009 was presented for the first time at a major oncology conference [1] - The design of the Phase Ib clinical study for CS5001 was disclosed [1]